Head and Neck Cancer News and Research RSS Feed - Head and Neck Cancer News and Research

Head and Neck Cancer is cancer that arises in the head or neck region (in the nasal cavity, sinuses, lips, mouth, salivary glands, throat, or larynx [voice box]).
Research brief describes enrollment of first patient with TRK fusion cancer in LOXO-101 Phase 1 trial

Research brief describes enrollment of first patient with TRK fusion cancer in LOXO-101 Phase 1 trial

The University of Colorado Cancer Center and Loxo Oncology, Inc., a biopharmaceutical company focused on the discovery, development and commercialization of targeted cancer therapies, today announced the publication of a research brief in the online edition of the journal Cancer Discovery, describing the first patient with a tropomyosin receptor kinase (TRK) fusion cancer enrolled in the Phase 1 dose escalation trial of LOXO-101, the only selective TRK inhibitor in clinical development. [More]
Researchers use silk fibers to grow stem cells into salivary gland cells

Researchers use silk fibers to grow stem cells into salivary gland cells

The silkworm, which produces the essential ingredient for fine silk fabric, also plays a critical role in a new process designed to provide relief for millions of individuals with dry mouth, a devastating oral and systemic health issue. [More]
Physicians testify for tobacco companies that years of heavy smoking did not cause cancer cases

Physicians testify for tobacco companies that years of heavy smoking did not cause cancer cases

Despite scientific evidence to the contrary, a small group of otolaryngologists have repeatedly testified, on behalf of the tobacco industry, that heavy smoking did not cause the cancer in cases of dying patients suing for damages, according to a study by a Stanford University School of Medicine researcher. [More]
Ludwig, CRI launch clinical trials to evaluate immunotherapies for treatment of GBM and solid tumors

Ludwig, CRI launch clinical trials to evaluate immunotherapies for treatment of GBM and solid tumors

Ludwig Cancer Research and the Cancer Research Institute have launched clinical trials evaluating an immunotherapy for the treatment of the brain cancer glioblastoma multiforme (GBM), and a combination of immunotherapies for a variety of solid tumors. [More]
Alabama scientists show how phytochemical in magnolia works against head and neck cancers

Alabama scientists show how phytochemical in magnolia works against head and neck cancers

Magnolias are prized for their large, colorful, fragrant flowers. Does the attractive, showy tree also harbor a potent cancer fighter? [More]
PNP Therapeutics granted FDA orphan drug designation for Gedeptin

PNP Therapeutics granted FDA orphan drug designation for Gedeptin

PNP Therapeutics Inc. announced today the Food and Drug Administration has granted orphan drug status to Gedeptin, the Company's lead product candidate (adenoviral vector expressing E. coli purine nucleoside phosphorylase gene) for the intratumoral treatment of anatomically accessible oral and pharyngeal cancers, including cancers of the lip, tongue, gum, floor of mouth, salivary gland and other oral cavities. [More]
OncoSec enrolls first patient in Phase II trial of ImmunoPulse IL-12 for treatment of HNSCC

OncoSec enrolls first patient in Phase II trial of ImmunoPulse IL-12 for treatment of HNSCC

OncoSec Medical Inc., a company developing DNA-based intratumoral cancer immunotherapies, announced today that the company has enrolled the first patient into OMS-I130, a Phase II clinical trial of ImmunoPulse IL-12 in patients with treatment-refractory, metastatic and unresectable squamous cell carcinoma of the head and neck (HNSCC). [More]
FDA clears ADXS-HPV plus epacadostat IND for HPV-associated cervical cancer Phase 2 study

FDA clears ADXS-HPV plus epacadostat IND for HPV-associated cervical cancer Phase 2 study

Advaxis, Inc., a clinical-stage biotechnology company developing cancer immunotherapies, today announced the clearance of the Investigational New Drug application by the United States Food and Drug Administration to conduct a Phase 2 study of ADXS-HPV (ADXS11-001) alone or in combination with Incyte Corporation's investigational oral indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor, epacadostat (INCB24360), for the treatment of Stage I-IIIb human papillomavirus (HPV)-associated cervical cancer. [More]
Amgen and Merck expand collaboration for Talimogene laherparepvec-KEYTRUDA combination study

Amgen and Merck expand collaboration for Talimogene laherparepvec-KEYTRUDA combination study

Amgen and Merck, known as MSD outside the U.S. and Canada, today announced an expanded collaboration to evaluate the efficacy and safety of talimogene laherparepvec, Amgen's investigational oncolytic immunotherapy, in combination with KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy, in a Phase 1, open-label trial of patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN). [More]
Penn researchers to present clinical data at 2015 ASCO Annual Meeting

Penn researchers to present clinical data at 2015 ASCO Annual Meeting

Researchers from the Abramson Cancer Center of the University of Pennsylvania and Penn's Perelman School of Medicine will present results from several clinical trials and other key studies during the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting from May 29 through June 2. [More]
Pembrolizumab (Keytruda) effective in patients with recurrent or metastatic head and neck cancer

Pembrolizumab (Keytruda) effective in patients with recurrent or metastatic head and neck cancer

Immunotherapy with the anti-PD-1 antibody pembrolizumab (Keytruda) was effective in one out of four patients with recurrent or metastatic head and neck cancer, according to results presented at the 2015 meeting of the American Society for Clinical Oncology. [More]
OSU researchers find promising approach to treating epithelial cancer

OSU researchers find promising approach to treating epithelial cancer

Researchers at Oregon State University are pursuing a new concept in treatment of epithelial cancer, especially head and neck cancer, by using two promising "analogs" of an old compound that was once studied as a potent anti-tumor agent, but long ago abandoned because it was too toxic. [More]
Humanized mouse model may lead to better anti-cancer therapies

Humanized mouse model may lead to better anti-cancer therapies

Human tumors grown in mouse models have long been used to test promising anti-cancer therapies. However, when a human tumor is transplanted into a mouse, the mouse immune system must be knocked down so that it doesn't attack the foreign tumor tissue, thus allowing the tumor to grow. [More]
Study points to TMPRSS2 gene as culprit for aggressive forms of androgen-fuelled cancers

Study points to TMPRSS2 gene as culprit for aggressive forms of androgen-fuelled cancers

A new study led by University of Toronto researcher Dr. David Lam has discovered the trigger behind the most severe forms of cancer pain. Released in top journal Pain this month, the study points to TMPRSS2 as the culprit: a gene that is also responsible for some of the most aggressive forms of androgen-fuelled cancers. [More]
New method for measuring genetic variability may help identify patients with aggressive cancers

New method for measuring genetic variability may help identify patients with aggressive cancers

A new method for measuring genetic variability within a tumor might one day help doctors identify patients with aggressive cancers that are more likely to resist therapy, according to a study led by researchers now at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute. [More]
UQDI reveals that Anisina drug can kill melanoma cells

UQDI reveals that Anisina drug can kill melanoma cells

US-Australian drug discovery company, Novogen, today announced that studies conducted at The University of Queensland Diamantina Institute revealed that experimental drug, Anisina, killed melanoma cells irrespective of their mutational status. [More]
Oral, Head & Neck Cancer Awareness Week: Mount Sinai experts to share tips on cancer prevention

Oral, Head & Neck Cancer Awareness Week: Mount Sinai experts to share tips on cancer prevention

Mouth and throat cancers are the fastest rising cancers today. They account for over 40,000 cases per year in the U.S. The American Cancer Society estimates that there will be 121,790 new cases of head and neck cancer diagnosed in 2015 and 14,240 deaths. These numbers include tongue cancer, throat cancers caused by the human papillomavirus or HPV, voice box cancer, melanoma of the face and thyroid cancers. [More]
HPV may cause oropharyngeal cancer

HPV may cause oropharyngeal cancer

Tobacco and alcohol use may be the most common cause of head and neck cancers, but a new culprit has come on the scene in recent years. [More]
Aging associated with development of dysphagia

Aging associated with development of dysphagia

Nearly 40 percent of Americans 60 and older are living with a swallowing disorder known as dysphagia. Although it is a major health problem associated with aging, it is unknown whether the condition is a natural part of healthy aging or if it is caused by an age-related disease that has yet to be diagnosed, such as Parkinson's disease or amyotrophic lateral sclerosis (ALS). [More]
Harry Folk speaks about successful throat cancer treatment received at St. Luke’s Cancer Center

Harry Folk speaks about successful throat cancer treatment received at St. Luke’s Cancer Center

It’s been nine years since Harry Folk of Palmer Township had a scare with throat cancer. He is able to talk about his journey, literally, thanks to the treatment he received at St. Luke’s. The treatment plan recommended by his cancer team not only removed his cancer, but preserved his voice and ability to swallow without difficulty. [More]
Advertisement